Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07518186 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma

Study acronym: TRIlogy-5
StatusRecruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

  1. Lead sponsor: Janssen Research & Development, LLC to Janssen Research & Development, LLC Trial sites expanded: 151 → 173 locations · Eligibility criteria expanded, about 8 words · Secondary endpoints: details revised at 10 of 21 entries Show 3 more changesShow less
    • Trial sites expanded: 151 → 173 locations
    • Eligibility criteria expanded, about 8 words
    • Secondary endpoints: details revised at 10 of 21 entries
  2. Trial sites expanded: 88 → 151 locationsv7
  3. Trial sites expanded: 29 → 88 locationsv6
  4. Trial sites expanded: 8 → 29 locationsv5
  5. Recruitment opened Trial sites expanded: 0 → 8 locations · Start date changed from estimate of Jun 8, 2026 to May 31, 2026v4 Show 2 more changesShow less
    • Trial sites expanded: 0 → 8 locations
    • Start date changed from estimate of Jun 8, 2026 to May 31, 2026
Show 2 earlier versionsHide 2 earlier versions
  1. Re-verified, no change to tracked fieldsv3
  2. Start date: Jun 9, 2026 to Jun 8, 2026v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this study is to evaluate how well JNJ-79635322 works when compared with teclistamab.
Trial Details
NCT Number NCT07518186
Lead Sponsor Janssen Research & Development, LLC
Conditions Multiple Myeloma
Enrollment 700 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov